PT72516B - Process for preparing hypoglycemic guanylamidines - Google Patents

Process for preparing hypoglycemic guanylamidines

Info

Publication number
PT72516B
PT72516B PT72516A PT7251681A PT72516B PT 72516 B PT72516 B PT 72516B PT 72516 A PT72516 A PT 72516A PT 7251681 A PT7251681 A PT 7251681A PT 72516 B PT72516 B PT 72516B
Authority
PT
Portugal
Prior art keywords
guanylamidines
preparing hypoglycemic
hypoglycemic
preparing
hypoglycemic guanylamidines
Prior art date
Application number
PT72516A
Other languages
English (en)
Other versions
PT72516A (en
Inventor
David Stewart Watt
Jeffrey Lee
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PT72516A publication Critical patent/PT72516A/pt
Publication of PT72516B publication Critical patent/PT72516B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT72516A 1980-02-19 1981-02-17 Process for preparing hypoglycemic guanylamidines PT72516B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/122,155 US4269837A (en) 1980-02-19 1980-02-19 Hypoglycemic guanylamidines, compositions and use

Publications (2)

Publication Number Publication Date
PT72516A PT72516A (en) 1981-03-01
PT72516B true PT72516B (en) 1982-10-21

Family

ID=22401029

Family Applications (1)

Application Number Title Priority Date Filing Date
PT72516A PT72516B (en) 1980-02-19 1981-02-17 Process for preparing hypoglycemic guanylamidines

Country Status (18)

Country Link
US (1) US4269837A (pt)
EP (1) EP0034495B1 (pt)
JP (1) JPS56147760A (pt)
KR (1) KR840000930B1 (pt)
AR (1) AR229350A1 (pt)
AT (1) ATE3425T1 (pt)
AU (1) AU517843B2 (pt)
CA (1) CA1145334A (pt)
DE (1) DE3160290D1 (pt)
DK (1) DK70881A (pt)
ES (1) ES499572A0 (pt)
FI (1) FI75343C (pt)
GR (1) GR78339B (pt)
IE (1) IE50924B1 (pt)
IL (1) IL62146A (pt)
PH (1) PH15971A (pt)
PT (1) PT72516B (pt)
YU (1) YU41968B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404219A (en) * 1980-03-31 1983-09-13 Pfizer Inc. Phenylguanidine therapeutic agents
US5268373A (en) * 1992-07-28 1993-12-07 Mcneilab, Inc. Guanidine derivatives, compositions and use
EP0805153B1 (en) * 1996-04-30 2001-11-14 Pfizer Inc. Novel muscarinic receptor agonists
AR008290A1 (es) * 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH478802A (de) 1966-09-06 1969-09-30 Sandoz Ag Verfahren zur Herstellung von Pyrazolderivaten
CS225804B2 (cs) 1976-03-19 1984-02-13 Mcneilab Inc Způsob výroby heterocyklických derivátů guanidinu

Also Published As

Publication number Publication date
IL62146A (en) 1984-09-30
IE50924B1 (en) 1986-08-20
ES8201541A1 (es) 1981-12-16
CA1145334A (en) 1983-04-26
YU39881A (en) 1983-09-30
DK70881A (da) 1981-08-20
IL62146A0 (en) 1981-03-31
FI75343C (fi) 1988-06-09
JPS6348265B2 (pt) 1988-09-28
EP0034495B1 (en) 1983-05-18
KR830005188A (ko) 1983-08-03
JPS56147760A (en) 1981-11-16
EP0034495A2 (en) 1981-08-26
ES499572A0 (es) 1981-12-16
DE3160290D1 (en) 1983-07-07
PH15971A (en) 1983-05-11
KR840000930B1 (ko) 1984-06-29
EP0034495A3 (en) 1982-01-27
FI75343B (fi) 1988-02-29
AR229350A1 (es) 1983-07-29
GR78339B (pt) 1984-09-26
IE810311L (en) 1981-08-19
PT72516A (en) 1981-03-01
FI810492L (fi) 1981-08-20
AU517843B2 (en) 1981-08-27
ATE3425T1 (de) 1983-06-15
US4269837A (en) 1981-05-26
YU41968B (en) 1988-04-30

Similar Documents

Publication Publication Date Title
PT72460A (en) Process for preparing sulfamoyl-substituted phenethylaminederivatives
PL234007A1 (en) Process for preparing novel imidazolylphenylamidines
PT73817A (en) Process for preparing 2-guanidino-4-heteroarylthiazoles
PT73671A (en) Process for preparing isoxazolylbenzamides
GB2082172B (en) Process for preparing n-alkyl-alkylenediamines
PT73211A (en) Process for preparing thiophenesulphonamides
PT73288B (en) Process for preparing tylactone
YU141080A (en) Process for preparing n-chlorocarbonl-lactams
PT73383B (en) Process for preparing 1-chloro-1-p-methoxybenzoylformaldoxime- n-methil-carbamate
PT72840B (en) Process for preparing phenyl-quinolizidines
PT72348A (en) Process for preparing kijanimicin
PT72733A (en) Process for preparing an insulin
PT72516B (en) Process for preparing hypoglycemic guanylamidines
DE3160358D1 (en) Process for preparing aryl-phosphonyl compounds
DE3161061D1 (en) Process for preparing arylacetaldehydes
PL232567A1 (en) Process for preparing 11-hydroxy-13-oxa-prostaglandin
DE3161108D1 (en) Process for preparing cyclopentenolones
PT73645B (en) Process for preparing new 4-carbamoyloxy-oxazaphosphorinns
PL241645A1 (en) Process for preparing novel 2-guanidine-4-heteroarylothiazoles
DE3165126D1 (en) Process for preparing cyclopentenolones
DE3166274D1 (en) Process for preparing v-triazole compounds
PT72679A (en) Process for preparing 2-haloacetanilides
DE3160081D1 (en) Process for preparing dimethyl-polysulfides
DE3168346D1 (en) Process for preparing n-cyanolactames
YU41444B (en) Process for preparing proscillaridin -4- methylether